Assessing the impact of the adoption of a continuous ketogenic diet therapy on the efficacy of combination chemo-immunotherapy using paclitaxel/carboplatin/pembrolizumab in advanced squamous cell cancer of the lung.
The KETO-Lung trial is investigating whether Squamous cell lung cancer (LUSC) could respond to dietary change using a ketogenic diet as therapy (KDT), enabling both chemotherapy and immunotherapy to work more effectively, hopefully improving current outcomes. We are aiming to include 48 patients with LUSC to find out whether adding a continuous ketogenic diet therapy improves how long patients live, delays the growth of their tumour and/or improves their quality of life.
The trial is run by CRCTU and led by Professor Gary Middleton (Chief Investigator) at the University of Birmingham. This trial is funded by Cancer Research UK and sponsored by the University of Birmingham.
Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating doctor to discuss trials for which they may be eligible.
Contact us
KETO-Lung Trial Office
Cancer Research UK Clinical Trials Unit (CRCTU)
School of Medical Sciences
University of Birmingham
Edgbaston, Birmingham
B15 2TT
keto-lung@trials.bham.ac.uk